

# CLINICAL PRACTICE GUIDELINES – HOW AND WHY?

Dr Stephen Ward

Consultant in Pain Medicine

Brighton and Sussex University Hospitals

# DECLARATIONS

- I am a full time pain specialist working in the NHS and private sector
- Member of the Evidence Analysis Committee - SIS
- Chair – NICE guideline on low back pain and sciatica 2016
- Chair – NICE guideline on rheumatoid arthritis 2017
- Chair – EFIC European low back pain guideline taskforce
- Expert advisor to the NICE Centre for Guidelines
- MSc student at Oxford University (medical statistics)

[All](#)[Images](#)[Shopping](#)[Videos](#)[News](#)[More ▾](#)[Search tools](#)

About 6,200,000 results (0.50 seconds)

## Shop for NICE BACK PAIN CHAIR on Google

Sponsored ⓘ



Posture  
Kneeling Stool  
£84.00  
Rainbow Zebra



Cobhamly  
Luxury mesh  
£131.99  
ChairOffice



Aurora Posture  
Chair Black  
£384.00  
Kit Out My Offi.



Herman Miller  
Sayl ...  
£291.72  
Office Chairs...



Backboard -  
Versatile Chair  
£42.49  
Backpain Help



Paris  
Orthopaedic ...  
£175.20  
Betterlife.co.uk



## Obusforme Posture Chairs - Obusforme Chiropractor Chairs

[Ad www.officefurnitureonline.co.uk/ ▾](http://www.officefurnitureonline.co.uk/)

3.9 ★★★★★ rating for officefurnitureonline.co.uk

Best Prices and Free Delivery!

[Bad Back Chairs](#)[Obusforme Visitor Chairs](#)[Obusforme Medium Back](#)[Obusforme High Back](#)

## The Sacro Wedgy® - SacroWedgy.com

[Ad www.sacrowedgy.com/ ▾](http://www.sacrowedgy.com/)

a tool that provides relief from sciatica and muscle imbalance

## Which Is The Best Office Chair For My Back Pain? - Back in Action

[https://www.backinaction.co.uk/office-chairs-which ▾](https://www.backinaction.co.uk/office-chairs-which)

At Back in Action we cater to your individual needs. We understand that there is not one chair that fits all, but with our specialist ergonomic advice and guidance, ...

## Top 10 Best Ergonomic Office Chairs 2016-15 + Editors Pick - Omnicore

[www.omnicoreagency.com](http://www.omnicoreagency.com) > [Business ▾](#)

Jump to [Best Ergonomic Office Chairs for Lower Back Pain](#) - An ergonomic office chair can do wonders to alleviate lower back pain that can affect ...


# BACK PAIN GUIDELINES

## BACK PAIN: HISTORY

- Hippocrates (460 BC- 375 BC) : 'Ischiatic pain'
- Pliny (23-79 AD) 'Sexual Intercourse is good for lower back pain, for weakness of the eyes, for derangement and depression 28.155
- Galen (130 AD – 210 AD) : 'Socles, promising to set Diodorus' crooked back straight, piled three solid stones, each four feet square, on the hunchbacks spine. He was crushed and died, but he has become straighter than a ruler.'  
Book XI – 120

## BACK PAIN: HISTORY

‘For a pine in the back take fresh cow dung and fry it in vinegar and apply it plaster wise to the back: you will little think how soon it will give you ease:



## BACK PAIN: HISTORY

‘The slimy substance of the root made in a posset of ale, and given to drinke against the paine in the backe gotten by any violent motion, as wrestling or ouermuch use of women, doth in foure or five days presently cure the same, although the involuntarie flowing of the seed in man be gotten’

The root of Comfrey hath a cold qualitic, but yet not much: it is also of a clammy and gluing moisture, it causeth no itch at all, neither is it of a sharpe or biting taste, but vsauorie or without taste; so farre is the tough and gluing moisture from the sharpe clamminesse of the sea Onion, as that there is no comparison betweene them. The leaues may cause itching not through heate or sharpenesse, but through their ruggednesse, as we haue already written, yet lesse than those of the Nettle.

### ¶ The Vertues.

The roots of Comfrey stamped, and the iuyce drunke with wine, helpeth those that spit bloud, A and healeth all inward wounds and burstings.


The same bruised and layd to in manner of a plaister, doth heale all fresh and green wounds, and B are so glutinatie, that it wil soder or glew together meat that is chopt in pieces, seething in a pot, and make it in one lumpe.

The roots boiled and drunke, do cleanse the brest from flegme, and cure the griefes of the lungs, C especially if they be confect with sugar and syrrup: it preuaileth much against ruptures or burstings.

The slimy substance of the root made in a posset of ale, and giuen to drinke against the paine in D the backe gotten by any violent motion, as wrestling, or ouermuch vse of women, doth in foure or five days presently cure the same, although the involuntarie flowing of the seed in man be gotten



# BACK PAIN: HISTORY





## BACK PAIN: HISTORY

# SNAKE-OIL LINIMENT

## RELIEVES INSTANTANEOUSLY

**AND CURES** HEADACHE, NEURALGIA, TOOTHACHE, EARACHE, BACKACHE, SWELLINGS, SPRAINS, SORE CHEST, SWELLING of the THROAT, CONTRACTED CORDS and MUSCLES, STIFF JOINTS, WRENCHES, DISLOCATIONS, CUTS and BRUISES.

**It Quickly takes out the Soreness and Inflammation from Corns, Bunions, Insect and Reptile Bites.**

The best External Preparation for BYCICLISTS and ATHLETES. It makes the Muscles supple and Relaxes the Cords. Loosens the Joints and gives a feeling of Freshness and Vigor to the whole System.

## SNAKE-OIL LINIMENT CURES ALL ACHES AND PAINS.

If you are suffering from Rheumatism, ALWAYS take LA-CAS-KA internally for the Blood and use SNAKE-OIL LINIMENT externally. When used together we GUARANTEE A CURE in every instance or MONEY REFUNDED.

## If You Are Afflicted With DEAFNESS

Get Our Specially Prepared

# PURE Rattlesnake Oil



# BACK PAIN: HISTORY

**CURE OF DISEASE WITHOUT DRUGS OR MEDICINES.**  
 An Air-Tight Dry Cell Pocket Battery which furnishes 4000 Electro-Magnetic Vibrations Per Minute.  
 (Patented in U. S. and Foreign Countries A.D. 1893-99.)

Battery in Pocket with conducting cables; Armatures and Electrodes attached, for use in all Rheumatic cases upon retiring; armatures applicable to any part of body or limbs.

Battery in Pocket with conducting cables; Armatures and Electrodes attached for use in all cases of Nervous or Sick Headache, Neuralgia, Dizziness, Insomnia, or Sleeplessness.

Battery in Pocket with conducting cables and Adjustable Ear Nasal Electrodes, for use day or night, in all cases of Deafness, Catarrh, and Catarrhal Deafness.

**ARE you afflicted with either Partial or Total Deafness, or Catarrh, or Catarrhal Deafness, Rheumatism, Neuralgia, Lumbago, Gout, Nervous Debility, or any other Disease, from any cause or of any Length or Standing?**

If so, send your name and full Post-Office address for Illustrated Book containing sworn statement showing the positively permanent cures that have been effected in cases pronounced incurable, by means of mild, pleasant, continuous currents of Electricity of Low Intensity and Long Duration directly applied to the seat of the disease by any sufferer, allaying all inflammation, soothing the nerve centres, and producing healthy vibrations by means of the **DR. HUBER ELECTRO-MAGNETIC DRY CELL POCKET MEDICAL BATTERY SUPPLIED WITH CONDUCTING CABLES. ARMATURES TO FIT ANY PART OF BODY OR LIMBS, AND ADJUSTABLE EAR AND NASAL ELECTRODES.** They can be worn in pocket day or night, but chiefly at night upon retiring, without the least inconvenience. Invariably produces sound, refreshing sleep. Duplicate cells always ready and sent prepaid by mail. No waste. No acids or disagreeable odors. Always ready for immediate use. A child can perfectly operate one. **The Battery and different Appliances can be used by all the members of an entire family for various ailments.** Their success has been so thoroughly established that perfect satisfaction is guaranteed in all cases. **Price, \$7.50 to \$12.50, according to Appliances needed.** Sent C. O. D. with privilege of full examination. Charges prepaid. **Trial of Batteries and Appliances and Electrodes in Office, FREE!** In the Ladies' Department of our business a thoroughly competent and experienced woman is always present to give instructions for use of all appliances.

Address **THE DR. HUBER DRY CELL POCKET MEDICAL BATTERY CO.**  
 No. 88 Fifth Avenue (3d door above 14th St.), New York City.

© Science Photo Library

# BACK PAIN TREATMENTS

Heat  
Cold  
Massage  
Acupuncture  
Yoga  
Tai Chi  
Qui Gong  
Exercise  
Bed rest  
Corsets  
Shoes  
Orthotics  
Laser  
Reiki

TENS  
Magnets  
Transcranial magnets  
Botox  
Trigger point  
Vitamin D  
NSAIDs  
Opiates  
Gabapentinoids  
Diazepam  
Biologics  
MBR  
Stem cells  
Homeopathy

Manipulation  
CBT  
ACT  
Mindfulness  
Facet joint injections  
Facet joint denervation  
Epidurals  
Ergonomics  
Disc replacement  
Spinal fusion  
Spinal spacers  
CFT  
Ultrasound  
Alexander

Hyaluronic acid  
Spinal cord stimulation  
Field stimulation  
Hypnosis  
Traction  
Acupressure  
Hydrotherapy  
Self management  
Herbal medicines  
Inversion tables  
Hyperbaric O2  
Ozone  
Infra red  
Woollen underpants

Rank <sup>a</sup>	Condition	Assigned Aggregated Condition Category	2013 Spending (Billions of Dollars), \$	Annualized Rate of Change, 1996-2013, %
	All conditions		2100.1	3.5
1	Diabetes mellitus	Diabetes, urogenital, blood, and endocrine diseases	101.4	6.1
2	Ischemic heart disease	Cardiovascular diseases	88.1	0.2
3	Low back and neck pain	Musculoskeletal disorders	87.6	6.5
4	Treatment of hypertension	Treatment of risk factors	83.9	5.1

Dieleman et al. US Spending on Personal Health Care and Public Health, 1996-2013 JAMA 2016

Leading causes 1990	Leading causes 2005	% change number of YLDs 1990-2005	% change all-age YLD rate 1990-2005	% change age-standardised YLD rate 1990-2005	Leading causes 2015	% change number of YLDs 2005-15	% change all-age YLD rate 2005-15	% change age-standardised YLD rate 2005-15
1 Lower back and neck pain	1 Lower back and neck pain	34.5	9.4	-1.8	1 Lower back and neck pain	18.6	4.9	-2.1
2 Iron-deficiency anaemia	2 Sense organ diseases	39.4	13.4	2.1	2 Sense organ diseases	25.2	10.8	0.6
3 Sense organ diseases	3 Iron-deficiency anaemia	14.8	-6.6	-0.6	3 Depressive disorders	18.2	4.5	1.0
4 Depressive disorders	4 Depressive disorders	32.9	8.0	0.6	4 Iron-deficiency anaemia	-3.8	-14.9	-11.6
5 Skin diseases	5 Skin diseases	21.9	-0.8	0.5	5 Skin diseases	11.7	-1.2	0.4
6 Migraine	6 Migraine	29.7	5.5	-0.3	6 Diabetes	32.5	17.2	5.4
7 Other musculoskeletal disorders	7 Other musculoskeletal disorders	51.8	23.4	13.5	7 Migraine	15.3	2.0	0.8
8 Anxiety disorders	8 Diabetes	69.2	37.6	20.7	8 Other musculoskeletal disorders	20.5	6.6	1.3
9 Diabetes	9 Anxiety disorders	26.1	2.6	-1.5	9 Anxiety disorders	14.8	1.5	1.0
10 Asthma	10 Asthma	2.6	-16.5	-15.5	10 Oral disorders	22.4	8.2	-0.2
11 Oral disorders	11 Oral disorders	33.9	8.9	-1.6	11 Asthma	9.4	-3.3	-2.3
12 Falls	12 Schizophrenia	36.1	10.7	0.7	12 Schizophrenia	19.5	5.7	0.3
13 Schizophrenia	13 Falls	13.4	-7.8	-13.9	13 Osteoarthritis	34.8	19.2	3.9
14 COPD	14 COPD	22.2	-0.6	-9.8	14 COPD	16.2	2.8	-5.9
15 Autistic spectrum	15 Osteoarthritis	53.0	24.4	6.3	15 Falls	11.3	-1.5	-8.6
16 Haemoglobinopathies	16 Gynaecological diseases	29.1	5.0	-3.4	16 Autistic spectrum	12.3	-0.7	0.6
17 Gynaecological diseases	17 Autistic spectrum	23.2	0.2	0.5	17 Gynaecological diseases	10.7	-2.1	-3.3
18 Intestinal nematode	18 Other mental and substance	32.5	7.8	0.2	18 Drug use disorders	23.6	9.4	8.2
19 Osteoarthritis	19 Drug use disorders	42.1	15.6	11.6	19 Other mental and substance	18.7	5.0	0.3
20 Other mental and substance	20 Haemoglobinopathies	10.8	-9.9	-5.3	20 Medication overuse headache	18.9	5.2	0.6
21 Bipolar disorder	21 Bipolar disorder	29.4	5.2	0.1	21 Bipolar disorder	14.9	1.6	0.5
22 Epilepsy	22 Medication overuse headache	32.6	7.9	-1.5	22 Congenital anomalies	28.5	13.7	14.7
23 Medication overuse headache	23 Epilepsy	10.9	-9.8	-7.9	23 Haemoglobinopathies	4.3	-7.7	-4.9
24 Other unintentional	24 Congenital anomalies	48.9	21.1	22.4	24 Chronic kidney disease	23.8	9.5	0.1
25 Drug use disorders	25 Chronic kidney disease	35.3	10.1	-2.4	25 Ischaemic heart disease	30.2	15.2	-0.3
26 Diarrhoeal diseases	26 Conduct disorder	15.8	-5.8	0.7	26 Alzheimer's disease	38.8	22.8	1.1
27 Conduct disorder	27 Other unintentional	0.7	-18.1	-23.6	27 Cerebrovascular disease	20.7	6.8	-4.2
28 Chronic kidney disease	28 Alcohol use disorders	28.2	4.2	-2.5	28 Alcohol use disorders	11.1	-1.7	-4.5
29 Congenital anomalies	29 Ischaemic heart disease	40.7	14.4	-2.7	29 Epilepsy	-6.4	-17.2	-16.3
30 Alcohol use disorders	30 Diarrhoeal diseases	-2.2	-20.5	-9.9	30 Other cardiovascular	23.9	9.6	0.5
33 Cerebrovascular disease	31 Cerebrovascular disease				33 Conduct disorder			
34 Ischaemic heart disease	33 Alzheimer's disease				34 Other unintentional			
36 Other cardiovascular	34 Other cardiovascular				35 Diarrhoeal diseases			
40 Alzheimer's disease	39 Intestinal nematode				46 Intestinal nematode			

Communicable, maternal, neonatal, and nutritional  
Non-communicable  
Injuries

# WHY DO WE NEED CLINICAL GUIDELINES?

‘Systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances’

Field MJ, Lohr KN. Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press; 1990

- To make sense of ‘Information overload’ and to keep up to date
- To ensure that effective, evidence based interventions are prioritised
- To prevent waste and harm
- To reduce variations in practice
- To provide a rational basis for referral
- To highlight areas where there is scientific uncertainty

# BACK PAIN GUIDELINES

## Quebec Task Force 1987

- Radiological examinations reduced to a minimum
- Reassurance, encourage return to work
- Bed rest limited to a few days
- NSAIDs
- Pain > 3 months: consult multidisciplinary team
- Review psychosocial aspects of pain
- Physical rehabilitation
- Indications for surgery must always be specific



# BACK PAIN GUIDELINES

- I. The Norwegian Guideline (The Norwegian Back Pain Network, 2002)
- II. New South Wales Guideline (New South Wales Therapeutic Assessment Group, 2002)
- III. National Practice Guidelines for Physical Therapy in Patients with Low Back Pain (KNGF 2003)
- IV. The New Zealand Guideline (New Zealand Guidelines Group, 2004)
- V. The Australian Guideline (Australian Acute Musculoskeletal Pain Guidelines Group, 2004)
- VI. European guidelines for the management of chronic nonspecific low back pain 2006
- VII. The University of Michigan Guideline (University of Michigan Health System, 2010)
- VIII. Low Back - Lumbar & Thoracic (Acute & Chronic) Guideline (Work Loss Data Institute, 2011)
- IX. 2007/2009/2017 Diagnosis and Treatment of Low Back Pain: APC &APS
- X. Low back and radicular pain: a pathway for care developed by the British Pain Society 2013
- XI. 2015 Evidence-Informed Primary Care Management of Low Back Pain – Canada
- XII. 2016 NICE low back pain and sciatica guideline.
- XIII. 2017 Danish low back pain guideline.



# BACK PAIN GUIDELINES

1. Identifying and refining the subject area.
  2. Convening and running a guideline development group.
  3. Assessing the evidence about the clinical question or condition, on the basis of systematic reviews.
  4. Translating the evidence into a recommendation.
  5. External review of the guideline.
- Original/de novo systematic review and meta analysis
  - Reviews of systematic reviews (+/- RCTs)
  - Reviews of previous guideline recommendations

## SYSTEMATIC REVIEWS

- 'No high-quality evidence shows that XXXXXXXX provides pain relief for patients with chronic low back pain'
- There was moderate quality evidence that XXXXXXXX results in larger improvements in pain and daily function than usual care.....

# NICE GUIDELINE NG59

**NICE** National Institute for  
Health and Care Excellence



## Low back pain and sciatica in over 16s: assessment and management


NICE guideline  
Published: 30 November 2016  
[nice.org.uk/guidance/ng59](https://www.nice.org.uk/guidance/ng59)

# NICE GUIDELINE NG59

- Scope
- Guideline development group
- Formulating questions
- PICO
- Search and analysis
- Presentation to GDG
- GDG consensus

# FOREST PLOT

**Figure 694: Pain severity (VAS 0–10) > 4 months**




# GDG DECISION MAKING

- Statistical significance of the primary efficacy analysis
- Magnitude of improvement in the primary efficacy outcome with treatment
- Results of responder analyses
- Treatment effect size compared to available treatments
- Rapidity of onset of treatment benefit
- Durability of treatment benefit
- Results for secondary efficacy endpoints
- Safety and tolerability
- Convenience
- Patient adherence
- Cost and cost effectiveness

## MINIMAL IMPORTANT DIFFERENCE

‘The smallest difference in score in the domain of interest which patients perceive as beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient’s management.’


Jaeschke et al 1989



Graph 1 – Mean pain intensity reported by patients before and after Pilates treatment.



## CLINICAL SIGNIFICANCE



# MID

‘It is crucial to recognize that criteria for clinically important changes in individuals cannot be extrapolated to the evaluation of group differences’

Dworkin R et al. Interpreting the clinical importance of group differences in chronic pain clinical

trials: IMMPACT recommendations. PAIN 146 (2009) 238–244

**Table 2.** Other characteristics of measures of the smallest worthwhile effect

Study	Outcomes <sup>a</sup>	Terminology	Method <sup>b</sup>	Specific <sup>c</sup>	Between/within? <sup>d</sup>	Who decided? <sup>e</sup>
Beurskens et al., 1996 [5]	D, BP, MC	MCID	A	No	Within	Res
Bronfort and Bouter, 1999 [17]	D, QoL	MCID	A	No	Within	Res
Chansirinukor et al., 2005 [18]	D	MDC	D	No	Within	Res
Childs and Piva, 2005 [19]	D	MCID	A	No	Within	Res
Childs et al., 2005b [20]	BP	MCID	A/D	No	Within	Res
Coelho et al., 2008 [21]	D, BP	MCID	A	No	Within	Res
Copay et al., 2008 [22]	BP, LP, D	MCID/MDC/MCID <sup>f</sup>	A/D	No	Within	Res
Davidson and Keating, 2002 [23]	D, BP	MDC	A	No	Within	Res
Demoulin et al., 2010a [8]	D	MIC	A	No	Within	Res
Demoulin et al., 2010b [9]	D	MIC	A	No	Within	Res
de Vet et al., 2007 [24]	BP	MIC	A/D	No	Within	Res
Farrar et al., 2001 [25]	BP	CII <sup>g</sup>	A	No	Within	Res
Ferreira et al., 2009 [26]	MC	SWE	PS	Yes	Within	Pts
Fritz and Irrgang, 2001 [27]	D	MCID	A	No	Within	Res
Grotle et al., 2004 [28]	D, BP, QoL	MCID	A	No	Within	Res
Hagg et al., 2003 [29]	D, BP, Dep	MCID	A	No	Within	Res
Jordan et al., 2006 [30]	D	1.96 SEM/SEM/MCID	A/D	No	Within	Res
Kovacs et al., 2007 [31]	BP, LP, D	MDC/MCID	A/D	No	Within	Res
Lauridsen et al., 2006 [32]	D, BP	MCID	A	No	Within	Res
Mannion et al., 2006 [33]	D, BP	MCIC	A	No	Within	Res
Maughan and Lewis, 2010 [43]	D, BP, PSE	MCID	A	No	Within	Res
Oliveira et al., 2009 [41]	MC	SWE	PS	Yes	Within	Pts
Ostelo et al., 2004 [34]	D, MC	MDC	D	No	Within	Res
Ostelo et al., 2008 [35]	D, BP	MIC	Other	No	Within	Res
Riddle et al., 1998 [36]	D	MCID	A	No	Within	Res
Sheldon et al., 2008 [37]	D, BP	MCIC	A	No	Within	Res
Strand et al., 2002 [42]	D	MCIC	A	No	Within	Res
Stratford et al., 1998 [38]	D	MCID	A	No	Within	Res
van der Roer et al., 2006 [39]	BP	MCIC-O <sup>h</sup> /MCIC/MDC	A/D	No	Within	Res
Williams et al., 1998 [40]	D	MCID	D	No	Within	Res
Yelland et al., 2006 [7]	D, BP	MWR <sup>i</sup>	Other	Yes	Unclear	Pts

<sup>a</sup> D, disability; BP, back pain; MC, main complaint; QoL, quality of life; LP, leg pain; Dep, depression; PSE, pain self efficacy.

<sup>b</sup> A, anchor-based methods; D, distribution-based methods; PS, patient-centered survey.

<sup>c</sup> Was the estimate intervention-specific?

<sup>d</sup> Was the estimate of a between- or within-person difference?

<sup>e</sup> Who decided if the effect was large enough? Res, researchers; Pts, patients.

<sup>f</sup> Derived from effect sizes.



<sup>g</sup> Clinically important improvement.

<sup>h</sup> MCIC-Optimal cut-off point.

<sup>i</sup> Minimum worthwhile percent reduction.

# EFFECT SIZE

$$\text{Effect Size} = \frac{[\text{Mean of experimental group}] - [\text{Mean of control group}]}{\text{Standard Deviation}}$$



# EFFECT SIZE

- Example:

## **VAS Pain**


$$\frac{4 \text{ (mean placebo group)} - 3 \text{ (mean intervention group)}}{2 \text{ (standard deviation)}}$$

Effect size = 0.5


(mean SD in 9076 subjects = 1.79)

## EFFECT SIZE

- Small = 0.2/0.3
- Medium = 0.5
- Large = 0.8



Interpretation



Cohen's  $U_3$




% Overlap



Probability of Superiority




Number Needed to Treat<sup>1</sup>



Interpretation



Cohen's  $U_3$



% Overlap




Probability of Superiority



Number Needed to Treat<sup>1</sup>







# QUALITY



# RECOMMENDATIONS






- DO NOT DO
- WEAK RECOMMENDATION
- STRONG RECOMMENDATION

## TREATMENT A

- Statistically significant 
- Pain VAS short term effect size VS placebo = 0.43 (I2: **3268**)
- Pain VAS long term effect size VS placebo 
- Pain VAS short term effect size VS usual care 
- Pain VAS long term effect size VS usual care 
- Function : +
- Cost effective N/A
- Harms ++





## OPIOIDS

## TREATMENT B

- Statistically significant 
- Pain VAS short term effect size VS placebo 
- Pain VAS long term effect size VS placebo 
- Pain VAS short term effect size VS usual care 0.26 (2: **82**)
- Pain VAS long term effect size VS usual care 
- Function : ++
- Cost effective 
- Harms -





YOGA

## TREATMENT C

- Statistically significant 
- Pain VAS short term effect size VS placebo 
- Pain VAS long term effect size VS placebo 
- Pain VAS short term effect size VS usual care = 0.32 (6: **456**)
- Pain VAS long term effect size VS usual care 
- Function : +/-
- Cost effective N/A
- Harms -


CBT

## TREATMENT D

- Statistically significant 
- Pain VAS short term effect size VS placebo = 1.16 (4: **167**)
- Pain VAS long term effect size VS placebo = 1.15 (3: **110**)
- Pain VAS short term effect size VS usual care 
- Pain VAS long term effect size VS usual care 
- Function : +/-
- Cost effective 
- Harms -

## RADIOFREQUENCY






## TREATMENT E

- Statistically significant 
- Pain VAS short term effect size VS placebo = 0.42 (8: **1760**)
- Pain VAS long term effect size VS placebo = 0.1 (5: **1458**)
- Pain VAS short term effect size VS usual care = 0.79 (8: **1334**)
- Pain VAS long term effect size VS usual care = 0.5 (3: **950**)
- Function : +/-
- Cost effective +/-
- Harms -

## ACUPUNCTURE






## TREATMENT F



- Statistically significant 
- Pain VAS short term effect size VS placebo 
- Pain VAS long term effect size VS placebo 
- Pain VAS short term effect size VS usual care 
- Pain VAS long term effect size VS usual care = 0.68 (I: **264**)
- Function : +
- Cost effective 
- Harms ++



## SPINAL FUSION

## TREATMENT G

- Statistically significant 
- Pain VAS short term effect size VS placebo 
- Pain VAS long term effect size VS placebo 
- Pain VAS short term effect size VS usual care = 0.2 (2: **106**)
- Pain VAS long term effect size VS usual care = 0.04 (1: **101**)
- Function : -
- Cost effective N/A
- Harms -

## SELF MANAGEMENT





## Visual summary

### Managing low back pain and sciatica

A brief overview the new NICE guidelines, from the perspective of a patient presenting in primary care.



Person with low back pain

With or without sciatica

#### Consider alternatives

Exclude specific causes of low back pain, for example:

Cancer Infection Trauma Inflammatory disease Cauda equina

Referral

#### X Imaging

Only consider imaging:

In specialist care and

If likely to alter management

#### Assess likely recovery outcomes

The complexity and intensity of treatment may vary depending on how likely it is that the patient will have a good functional outcome

Consider using risk stratification –such as the **STarT Back** risk assessment tool

Possible indicators of poor outcomes

Fear / pain avoidance Low mood Job dissatisfaction Ongoing litigation

Good Likely outcomes Poor

#### Provide self management information

Information on nature of pain

Encouragement to continue activities

Self management is important for all patients, even those with acute symptoms and/or sciatica

#### Managing acute sciatica

Neuropathic pain medication

Epidural injections

Steroid

+

Local anaesthetic

Spinal decompression

After acute symptoms of sciatica are controlled, it may be appropriate to (re)enter an exercise programme to manage underlying low back pain

To manage a specific episode

Group exercise

+

Manual therapy

+

Psychological therapy

Pain is persistent / treatment resistant

Combined physical + psychological programme

#### Consider pain relief options

Paracetamol

X Not effective alone

NSAIDs\*

✓ Consider oral NSAIDs

Weak opioids

✓ If NSAID ineffective / not tolerated / contraindicated

X Do not offer acupuncture

\* NSAIDs = non-steroidal anti-inflammatory drugs